Denali Therapeutics (DNLI) Receivables - Other (2017 - 2022)

Denali Therapeutics (DNLI) has 5 years of Receivables - Other data on file, last reported at $357000.0 in Q2 2022.

• Receivables - Other for Q2 2022 came in at $357000.0, down 77.22% year-over-year; the trailing twelve-month figure through Jun 2022 was $357000.0 (down 77.22% YoY), and the FY2021 annual result was $1.2 million, down 78.39% from the prior year.
• Receivables - Other fell to $357000.0 in Q2 2022 per DNLI's latest filing, from $1.2 million in the prior quarter.
• Over five years, Receivables - Other peaked at $5.7 million in Q4 2020 and troughed at $357000.0 in Q2 2022.
• A 4-year average of $2.0 million and a median of $1.2 million in 2021 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2018 and 2021: Receivables - Other jumped 154.74% in 2018, then plunged 78.39% in 2021.
• A 4-year view of Receivables - Other shows it stood at $1.2 million in 2018, then jumped by 380.03% to $5.7 million in 2020, then sank by 78.39% to $1.2 million in 2021, then plunged by 70.88% to $357000.0 in 2022.
• Business Quant data shows DNLI's Receivables - Other at $357000.0 in Q2 2022, $1.2 million in Q4 2021, and $1.2 million in Q3 2021.